Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings

  • Background Medicines that are based on known molecules and are further developed to address healthcare needs and deliver relevant improvement for patients, healthcare professionals and/or payers are called value-added medicines (VAMs). The evaluation process of VAMs is heterogeneous across countries, and it has been primarily designed for originator pharmaceuticals with confirmatory evidence collected alongside pivotal clinical trials. There is a mismatch between evidence requirements by public decision-makers and evidence generated by manufacturers of VAMs. Our objective was to develop a core evaluation framework for VAMs. Methods Potential benefits offered by VAMs were collected through a systematic literature review and allocated to separate domains in an iterative process. The draft list of domains and their applicability were validated during two consecutive virtual workshops by health policy experts representing countries with different economic statuses, geographical and decision-making

Export metadata

Additional Services

Search Google Scholar
Metadaten
Author:Zsuzsanna Ida Petykó, Zoltán Kaló, Jaime Espin, Kateřina Podrazilová, Tomáš Tesař, Nikos Maniadakis, Frank-Ulrich Fricke, András InotaiORCiD
DOI:https://doi.org/10.1186/s12962-021-00311-6
ISSN:1478-7547
Parent Title (English):Cost Effectiveness and Resource Allocation
Publisher:Springer Science and Business Media LLC
Document Type:Article
Language:English
Reviewed:Begutachtet/Reviewed
Release Date:2024/11/26
Volume:19
Issue:1
Article Number:57
institutes:Fakultät Betriebswirtschaft
Licence (German):Creative Commons - CC BY - Namensnennung 4.0 International
Verstanden ✔
Diese Webseite verwendet technisch erforderliche Session-Cookies. Durch die weitere Nutzung der Webseite stimmen Sie diesem zu. Unsere Datenschutzerklärung finden Sie hier.